Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapy.

ABSTRACT: PTDSS1 (phosphatidylserine synthase 1) encodes an enzyme that facilitates production of phosphatidylserine (PS), which mediates a global immunosuppressive signal. Here, based on in vivo CRISPR screen, we identified PTDSS1 as a target to improve anti-PD-1 therapy. Depletion of Ptdss1 in tumor cells increased expression of interferon-γ (IFN-γ)-regulated genes, including B2m, Cxcl9, Cxcl10, and Stat1, even in the absence of IFN-γ stimulation in vitro. Loss of Ptdss1 in tumor cells also led to increased expression of MHC-I, enhanced cytotoxicity of CD8⁺ T cells, and increased frequency of an iNOS⁺ myeloid subset. A gene signature derived from the iNOS⁺ myeloid cell subset correlated with clinical benefit in patie

SUBMITTER: Liu J 

PROVIDER: S-EPMC12422196 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature